Ten killed, dozens injured in Turkey train derailment

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Islamabad, Jun 6: Pakistan has reported a record 97 COVID-19 deaths in a single day, taking the total number of fatalities to 1,935, while the number of confirmed cases in the country approached 94,000 after over 4,700 infections were detected, the health ministry said on Saturday.

Punjab registered 35,308 COVID-19 cases, Sindh 34,889, Khyber-Pakhtunkhwa 12,459, Balochistan 5,776 Islamabad 4,323, Gilgit-Baltistan 897 and Pakistan-occupied Kashmir 331 cases, the Ministry of National Health Services said.

The total number of COVID-19 cases reached 93,983 after 4,734 new infections were detected across the country, it said.

With a record 97 fatalities in one day, the death toll in the country has reached 1,935, while 32,581 people have recovered from the disease.

The ministry said that the total number of active COVID-19 cases in Pakistan are 59,467, out of which 1,265 patients are in critical condition.

More than 100 labs in the country have so far conducted 660,508 tests, including 22,185 in the last 24 hours.

There are 747 hospitals across the country with COVID-19 treatment facilities where 5,060 patients are being treated. Others have been asked to self-isolate at home.

Washington, May 20: The United States recorded another 1,536 coronavirus deaths over the past 24 hours, the Johns Hopkins University tracker said.

That figure, tallied as of 8:30 pm (0030 GMT), raises to 91,845 the total number of COVID-19 deaths in the US.

The US tops the global rankings both for the highest death toll and the highest number of infections, with more than 1.5 million cases.